Literature DB >> 29083319

HIV-antibody complexes enhance production of type I interferon by plasmacytoid dendritic cells.

Rebecca T Veenhuis1, Zachary T Freeman1, Jack Korleski1, Laura K Cohen1, Guido Massaccesi1, Alessandra Tomasi1, Austin W Boesch2, Margaret E Ackerman2, Joseph B Margolick3, Joel N Blankson1, Michael A Chattergoon1, Andrea L Cox1.   

Abstract

Type I IFN production is essential for innate control of acute viral infection; however, prolonged high-level IFN production is associated with chronic immune activation in HIV-infected individuals. Although plasmacytoid DCs (pDCs) are a primary source of IFN, the mechanisms that regulate IFN levels following the acute phase are unknown. We hypothesized that HIV-specific Ab responses regulate late IFN production. We evaluated the mechanism through which HIV-activated pDCs produce IFN as well as how both monoclonal HIV-specific Abs and Abs produced in natural HIV infection modulated normal pDC sensing of HIV. We found that HIV-induced IFN production required TLR7 signaling, receptor-mediated entry, fusion, and viral uncoating, but not endocytosis or HIV life cycle stages after uncoating. Abs directed against the HIV envelope that do not interfere with CD4 binding markedly enhanced the IFN response, irrespective of their ability to neutralize CD4+ T cell infection. Ab-mediated enhancement of IFN production required Fc γ receptor engagement, bypassed fusion, and initiated signaling through both TLR7 and TLR9, which was not utilized in the absence of Ab. Polyclonal Abs isolated from HIV-infected subjects also enhanced pDC production of IFN in response to HIV. Our data provide an explanation for high levels of IFN production and immune activation in chronic HIV infection.

Entities:  

Keywords:  AIDS/HIV; Dendritic cells; Immunoglobulins; Inflammation; Innate immunity

Mesh:

Substances:

Year:  2017        PMID: 29083319      PMCID: PMC5707144          DOI: 10.1172/JCI95375

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  70 in total

Review 1.  Plasmacytoid dendritic cells: linking innate and adaptive immunity.

Authors:  Kelli McKenna; Anne-Sophie Beignon; Nina Bhardwaj
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

2.  Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro.

Authors:  W E Robinson; M K Gorny; J Y Xu; W M Mitchell; S Zolla-Pazner
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

Review 3.  Type I interferon: understanding its role in HIV pathogenesis and therapy.

Authors:  Steven E Bosinger; Netanya S Utay
Journal:  Curr HIV/AIDS Rep       Date:  2015-03       Impact factor: 5.071

4.  Highly parallel characterization of IgG Fc binding interactions.

Authors:  Austin W Boesch; Eric P Brown; Hao D Cheng; Maame Ofua Ofori; Erica Normandin; Peter A Nigrovic; Galit Alter; Margaret E Ackerman
Journal:  MAbs       Date:  2014 Jul-Aug       Impact factor: 5.857

5.  The multicenter AIDS Cohort Study, 1983 to ….

Authors:  R Detels; L Jacobson; J Margolick; O Martinez-Maza; A Muñoz; J Phair; C Rinaldo; S Wolinsky
Journal:  Public Health       Date:  2011-12-27       Impact factor: 2.427

6.  Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region.

Authors:  M H Tao; S L Morrison
Journal:  J Immunol       Date:  1989-10-15       Impact factor: 5.422

7.  Blockade of chronic type I interferon signaling to control persistent LCMV infection.

Authors:  Elizabeth B Wilson; Douglas H Yamada; Heidi Elsaesser; Jonathan Herskovitz; Jane Deng; Genhong Cheng; Bruce J Aronow; Christopher L Karp; David G Brooks
Journal:  Science       Date:  2013-04-12       Impact factor: 47.728

8.  Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response.

Authors:  Béatrice Jacquelin; Véronique Mayau; Brice Targat; Anne-Sophie Liovat; Désirée Kunkel; Gaël Petitjean; Marie-Agnès Dillies; Pierre Roques; Cécile Butor; Guido Silvestri; Luis D Giavedoni; Pierre Lebon; Françoise Barré-Sinoussi; Arndt Benecke; Michaela C Müller-Trutwin
Journal:  J Clin Invest       Date:  2009-12       Impact factor: 14.808

Review 9.  Regulation of type I interferon responses.

Authors:  Lionel B Ivashkiv; Laura T Donlin
Journal:  Nat Rev Immunol       Date:  2014-01       Impact factor: 53.106

10.  Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.

Authors:  Dan H Barouch; James B Whitney; Brian Moldt; Florian Klein; Thiago Y Oliveira; Jinyan Liu; Kathryn E Stephenson; Hui-Wen Chang; Karthik Shekhar; Sanjana Gupta; Joseph P Nkolola; Michael S Seaman; Kaitlin M Smith; Erica N Borducchi; Crystal Cabral; Jeffrey Y Smith; Stephen Blackmore; Srisowmya Sanisetty; James R Perry; Matthew Beck; Mark G Lewis; William Rinaldi; Arup K Chakraborty; Pascal Poignard; Michel C Nussenzweig; Dennis R Burton
Journal:  Nature       Date:  2013-10-30       Impact factor: 49.962

View more
  10 in total

1.  SLAMF7 Is a Critical Negative Regulator of IFN-α-Mediated CXCL10 Production in Chronic HIV Infection.

Authors:  Patrick O'Connell; Yuliya Pepelyayeva; Maja K Blake; Sean Hyslop; Robert B Crawford; Michael D Rizzo; Cristiane Pereira-Hicks; Sarah Godbehere; Linda Dale; Peter Gulick; Norbert E Kaminski; Andrea Amalfitano; Yasser A Aldhamen
Journal:  J Immunol       Date:  2018-12-10       Impact factor: 5.422

Review 2.  HIV-1 Infection and Type 1 Interferon: Navigating Through Uncertain Waters.

Authors:  Sho Sugawara; David L Thomas; Ashwin Balagopal
Journal:  AIDS Res Hum Retroviruses       Date:  2018-08-15       Impact factor: 2.205

3.  People with HIV-1 demonstrate type 1 interferon refractoriness associated with upregulated USP18.

Authors:  Sho Sugawara; Ramy El-Diwany; Laura K Cohen; Kimberly E Rousseau; Christopher Y K Williams; Rebecca T Veenhuis; Shruti H Mehta; Joel N Blankson; David L Thomas; Andrea L Cox; Ashwin Balagopal
Journal:  J Virol       Date:  2021-03-03       Impact factor: 5.103

4.  Cross-reactive antibodies facilitate innate sensing of dengue and Zika viruses.

Authors:  Laura K Aisenberg; Kimberly E Rousseau; Katherine Cascino; Guido Massaccesi; William H Aisenberg; Wensheng Luo; Kar Muthumani; David B Weiner; Stephen S Whitehead; Michael A Chattergoon; Anna P Durbin; Andrea L Cox
Journal:  JCI Insight       Date:  2022-06-22

Review 5.  Sustained IFN-I Expression during Established Persistent Viral Infection: A "Bad Seed" for Protective Immunity.

Authors:  Xavier Dagenais-Lussier; Hamza Loucif; Armstrong Murira; Xavier Laulhé; Simona Stäger; Alain Lamarre; Julien van Grevenynghe
Journal:  Viruses       Date:  2017-12-30       Impact factor: 5.048

6.  Identification of key genes and pathways in regulating immune‑induced diseases of dendritic cells by bioinformatic analysis.

Authors:  Yang Zheng; Xianghui Zheng; Shuang Li; Hanlu Zhang; Mingyang Liu; Qingyuan Yang; Maomao Zhang; Yong Sun; Jian Wu; Bo Yu
Journal:  Mol Med Rep       Date:  2018-03-29       Impact factor: 2.952

7.  Toll-Like Receptor (TLR) Signaling Enables Cyclic GMP-AMP Synthase (cGAS) Sensing of HIV-1 Infection in Macrophages.

Authors:  Mohammad Adnan Siddiqui; Masahiro Yamashita
Journal:  mBio       Date:  2021-11-30       Impact factor: 7.867

8.  HIV and the liver.

Authors:  Kenneth E Sherman; Marion G Peters; David L Thomas
Journal:  Top Antivir Med       Date:  2019-09

Review 9.  SLAM Family Receptor Signaling in Viral Infections: HIV and Beyond.

Authors:  Patrick O'Connell; Andrea Amalfitano; Yasser A Aldhamen
Journal:  Vaccines (Basel)       Date:  2019-11-16

Review 10.  The cGAS/STING Pathway: A Novel Target for Cancer Therapy.

Authors:  Yu Gan; Xiaoying Li; Shuangze Han; Qi Liang; Xiaoqian Ma; Pengfei Rong; Wei Wang; Wei Li
Journal:  Front Immunol       Date:  2022-01-03       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.